Alaunos is developing our Sleeping Beauty platform in collaboration with The University of Texas MD Anderson Cancer and the National Cancer Institute.
MD Anderson Cancer Center
We are advancing our innovative T-cell receptor therapy platform in collaboration with The University of Texas MD Anderson Cancer Center. In 2015 we licensed foundational technology from MD Anderson Cancer Center.
National Cancer Institute (NCI)
In 2019, we entered into an Exclusive Patent License Agreement with the NCI to evaluate TCRs for patients with advanced cancers. This research is being led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI. Alaunos & the NCI team have also used the Sleeping Beauty platform to generate neoantigen-specific T cells to target solid tumors. The Sleeping Beauty system is able to target the unique mutations that give rise to a patient’s malignancy.